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Abstract  
 
Purpose  
Pregnancy prevention programmes (PPPs) exist for some medicines known to be highly 
teratogenic. It is increasingly recognised that the impact of these risk minimisation 
measures require periodic evaluation. This study aimed to assess the extent to which some 
of the data needed to monitor the effectiveness of PPPs may be present in European 
healthcare databases. 
 
Methods 
An inventory was completed for databases contributing to EUROmediCAT capturing 
pregnancy and prescription data in Denmark, Norway, the Netherlands, Italy 
(Tuscany/Emilia Romagna), Wales and the rest of the UK, to determine the extent of data 
collected that could be used to evaluate the impact of PPPs. 
 
Results 
Data availability varied between databases. All databases could be used to identify the 
frequency and duration of prescriptions to women of childbearing age from primary care, 
but there were specific issues with availability of data from secondary care and private care.  
To estimate the frequency of exposed pregnancies, all databases could be linked to 
pregnancy data, but the accuracy of timing of the start of pregnancy was variable, and data 
on pregnancies ending in induced abortions often not available. Data availability on 
contraception to estimate compliance with contraception requirements was variable and no 
data were available on pregnancy tests.   
 
Conclusion 
Current electronic healthcare databases do not contain all the data necessary to fully 
monitor the effectiveness of PPP implementation, and thus special data collection measures 
need to be instituted.  
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1.0 Introduction   
Risk minimisation measures aim to reduce the occurrence or severity of adverse drug 
reactions and improve the benefit-risk profile.[1] These measures range from routine 
requirements such as providing a patient information leaflet and summary of product 
characteristics, to special education programmes or controlled access programmes.[2, 3] 
Increasingly, the need to monitor the effectiveness or impact of risk minimisation measures 
in limiting adverse drug reactions is being discussed at a European level.[2, 3]  
 
Pregnancy prevention programmes (PPPs) are special risk minimisation measures, 
implemented when there is sufficient evidence to demonstrate that a product is highly 
teratogenic when used during pregnancy.[4-6] PPPs aim to allow women of childbearing 
potential to use these highly teratogenic products, when alternative treatments have failed, 
whilst ensuring they are not pregnant when they start treatment and do not become 
pregnant during treatment and within an appropriate time period after stopping 
treatment.[7] The precise components of PPPs vary depending on the product but commonly 
include: a requirement that the medicine should not be used as first line treatment, a 
requirement for women of childbearing potential to undergo pregnancy testing at specific 
time intervals before, during and following treatment, a requirement for the use of two 
methods of contraception, restrictions on the quantity of a product that can be issued in a 
single prescription, limits on the time-window that a prescription can be dispensed 
following the date of issue, and education material for the patient, prescriber and 
pharmacist.[8, 9] Products with a PPP include probably the best known of all teratogenic 
medicines, thalidomide, as well as more commonly used medicines, such as the 
dermatological acne medicines acitretin and isotretinoin.[10] Despite the implementation of 
PPPs, there is still evidence of women becoming pregnant whilst on treatment and of non-
compliance.[11-13] However, monitoring of the effectiveness of PPPs remains ad hoc. 
 
We aim here to assess the extent to which some of the data needed to monitor the 
effectiveness of PPPs may be present in some European electronic healthcare databases; 
focusing specifically on the ability to monitor the frequency of prescribing to women of 
 5 
 
childbearing age, compliance with PPP requirements concerning pregnancy testing and 
contraception, and the ability to identify exposed pregnancies and their outcomes.  
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2.0 Methods 
An inventory was completed for a sample of European databases that were contributing to 
the EUROmediCAT study,[14] a Seventh Framework Programme study funded by the 
European Union that aimed to make more systematic use of electronic healthcare databases 
in combination with EUROCAT[15] congenital anomalies data. The databases covered 
Denmark,[16-18] the Northern Netherlands, [19, 20] Norway,[21-23] two regions of Italy 
(Tuscany[24, 25] and Emilia Romagna[26]), Wales[27, 28] and the Clinical Practice Research 
Datalink (CPRD)[29, 30] capturing a sample of the rest of the UK. A summary of the databases 
can be found in Table 1 and has been reported elsewhere.[14] For each database, the 
inventory requested information on the population covered and the source of the 
information captured, the extent and availability of prescription data, data relating to 
contraception and pregnancy, patient characteristics and pregnancy outcomes. The 
inventory was completed based on the data available within the databases between 2004 
and 2012. For the EUROmediCAT study, the Danish databases were restricted to women 
who had a pregnancy during the study period, but data on all individuals are available 
subject to data access approvals and charges and this paper therefore reports on the full 
Danish databases.  
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3.0 Results 
The seven databases were all population-based and captured data from either an entire 
country/region or a sample of a country’s population (Table 1). For the remainder of this 
paper, for ease of reading, the databases will be referred to by the country or region they 
cover.  
 
3.1 Data to allow estimation of frequency of prescriptions to women of childbearing age 
and duration of treatment. 
All databases had data to allow identification of the timing of prescriptions issued 
(Wales/rest of the UK) or dispensed (Denmark, Italy, Norway and the Netherlands). 
However, there were limited data on private prescriptions and prescriptions issued in 
secondary care (Table 2), and secondary care prescriptions may be particularly important for 
medications with a PPP where prescribers are often restricted to specialists.  The duration of 
prescriptions could be estimated based on defined daily dose (DDD) data in the Italian and 
Norwegian databases, whilst in the UK, data was available on the prescribed daily dose 
(PDD) and in the Netherlands on the number of days prescribed (Table 2). The nature of 
DDD data means that it may not correspond directly to actual daily intake resulting in the 
estimates of prescription duration being less accurate than those with data on prescribed 
daily dose. 
 
In the UK, prescriptions issued by a specialist in secondary care were only likely to be 
captured if the GP chose to enter the information into the patient’s computer record 
following receipt of a letter from the specialist. For many products the specialist will initiate 
the prescribing and all subsequent prescribing will be carried out by the GP, however, for 
some products with a PPP such as isotretinoin, the PPP may state that all prescribing should 
only be carried out by a consultant-led team and issued from a hospital-based pharmacy.[31, 
32]  
 
In non-UK databases, prescribing data were based on prescriptions actually dispensed by a 
pharmacist. In Denmark, Norway and the Netherlands, all prescriptions with the exception 
of those issued to in-patients during a hospital stay were captured. In the Italian regions, 
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only prescriptions reimbursed by the Italian National Health Service were captured, this also 
excluded private prescriptions and those issued during an in-patient hospital stay. In Emilia 
Romagna, secondary care prescriptions and those dispensed at a hospital pharmacy for 
home use  have been captured at an individual patient level from 2009, and are considered 
to be reliable from 2011.  
 
No data on the indication for prescribing were available in the Italian or Dutch databases. In 
Norway, up until March 2008, only broad categories relating to indication were available 
before the introduction of more granular International Classification of Diseases (ICD) codes. 
Indication for prescribing was available in some cases in the UK and Wales databases while 
in Denmark, the Italian regions and also Wales this could sometimes be inferred from 
hospital discharge diagnoses or diagnostic codes (usually ICD 10 codes) relating to hospital 
out-clinic patient appointments.  
 
3.2 Data to allow identification of exposed pregnancies and pregnancy outcome 
Identification of exposed pregnancies usually requires linkage of data on pregnancies to 
data on prescriptions, except in the UK where primary care databases may contain all the 
relevant information (Table 2). 
 
All databases captured pregnancies that ended in a live delivery and all databases except 
the Netherlands captured data on stillbirths. Databases that could combine information on 
prescribing and the approximate start date of a pregnancy would therefore be able to 
identify a breakthrough pregnancy during treatment that ended in a live delivery (Table 3). 
The accuracy by which the timing of exposure could be determined was dependent on the 
information available on the start date of the pregnancy and this varied between databases: 
in the Norwegian and Wales databases the date of the first day of the last menstrual period 
was captured, in the Italian and Danish databases the pregnancy start date could be 
extrapolated from information on gestational age at delivery, in the CPRD, information on 
the last menstrual period was captured for ~40% and for the reminder an algorithm could 
be used to estimate the start date based on other records, including those relating to 
gestational age and estimated date of delivery, in the Netherlands no information was 
available and all pregnancies are assigned a default duration of 280 days.  
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Estimation of timing of exposure in relation to pregnancy is also dependent on the data on 
the timing of medication intake (see 3.1) and neither date issued nor date dispensed 
necessarily accurately reflects the time the prescription was self-administered, or whether it 
was definitely taken at all.   
 
Given the known teratogenic potential of products with a PPP, some women may decide to 
undergo a termination of pregnancy when they discover they have been unintentionally 
exposed during their pregnancy.[33] Databases that do not capture induced terminations are 
therefore likely to underestimate the incidence of breakthrough pregnancies among women 
using products with a PPP. Data on pregnancies that ended in an induced termination or 
spontaneous abortion were captured and available in the CPRD and Danish databases but in 
the other databases this information was either not captured or restricted. In the Emilia 
Romagna database there was no information on spontaneous abortions and it was not 
possible to link induced terminations to prescription data. In Tuscany, it was possible to link 
prescription data to records of pregnancies that ended in a termination, for any reason, 
provided the woman did not deny consent during her hospital stay. Less than 1% of 
terminations had a record of denied consent but only 55% of induced terminations and 44% 
of spontaneous abortions could be linked to the health discharge record and therefore had 
the potential to be linked to the prescription registry. In Wales, the data on induced 
terminations and spontaneous abortions at <24 weeks gestation are considered by the NHS 
Wales Informatics Service to be too sensitive to be used for research, and thus are not 
available in primary and secondary care records. In the Norwegian database, spontaneous 
abortions were captured from 12 gestational weeks (although these data are more reliable 
from 16 weeks) and induced terminations were captured only if they followed the diagnosis 
of a congenital anomaly. 
 
All databases (except the CPRD in the UK) could link to EUROCAT congenital anomaly 
registers to identify diagnosed congenital anomalies [34] (including livebirths, stillbirths and 
terminations of pregnancy for fetal anomaly), although in Denmark only a region capturing 
~8% of the population can be linked. In the CPRD, congenital anomalies may be recorded by 
the GP in the coded data and for pregnancies ending in a live birth it is possible to identify 
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these by linking the mother’s medical record to the medical record of the child;[30] the level 
of detail on the congenital anomaly, however, may not be as accurate/exhaustive or 
complete as that of the congenital anomaly registries. For pregnancies ending in an induced 
termination, identification of congenital anomalies is more difficult in the CPRD; an 
algorithm can be developed to identify pregnancy losses that appear to have ended in a 
termination for medical reasons but determining the precise reason and exact congenital 
anomaly is often not possible, especially now access to the anonymised free text comments 
is no longer available.  
 
 
3.3. Data to allow evaluation of compliance with PPP provisions on pregnancy tests and 
contraception among women of childbearing age/women with exposed pregnancies. 
 
No data were available on contraception within the Italian databases, as contraception is 
not reimbursed by the Italian National Health Service (Table 2). No databases provided data 
on barrier contraceptives, including condoms; although this will result in an underestimation 
of contraceptive use, a PPP usually recommends that the main form of contraception should 
be hormonal and will not sanction the use of only one barrier method. As a result you would 
expect to still capture women receiving other non-barrier methods of contraception. In all 
regions, other than Italy, data were available on the issue/prescribing of oral hormonal 
contraceptives, intrauterine devices, contraceptive implants and depot contraceptives. In 
Norway, data on intrauterine devices without hormones (e.g. ordinary copper devices) were 
not captured within the prescription database. In Wales and the rest of the UK, in normal 
circumstances, women have the option of going to family planning clinics for their 
contraception so not all contraceptives will be recorded in the databases. It is possible, 
however, that visiting a family planning clinic may be less likely for women who are under a 
PPP. When evaluating longer-lasting contraception methods, such as intrauterine devices 
which are effective for up to five years, not all women will have sufficient follow-up in the 
databases to determine whether they had received this method of contraception in the 
years prior to receipt of the PPP related prescription. Data on whether a woman did not 
require contraceptives because she had undergone a hysterectomy, oophorectomy, 
sterilisation or her husband/partner had undergone a vasectomy were more likely to be 
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captured in the databases in Denmark, Norway (from 2008), Wales and the rest of the 
United Kingdom than the other regions.  
In addition, none of the databases collected information on sexual activity and whether 
women were actually ‘at risk’ of becoming pregnant. 
 
 
Data on whether a woman had undergone a supervised pregnancy test, as required by a 
PPP, was not routinely captured in any of the data sources.  
 
3.4. Data to allow evaluation of factors that may influence compliance to PPPs to inform a 
more targeted approach to improve PPP compliance. 
 
The age of a woman at time of prescription was available in all databases which would also 
allow age specific rates of exposure to be calculated (Online supplement Table S1). All 
databases captured an indicator of socioeconomic status and co-prescribing, with several of 
the databases also containing information on comorbidities. Data on lifestyle factors, such 
as smoking status, alcohol and body mass index were largely available in the UK/Wales 
databases but were absent from many of the other databases. In Norway and Denmark, 
data on smoking status were only available for pregnant women and not all women of 
childbearing age as this was captured within the Medical Birth Registry, but not the Patient 
Registry.  
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Discussion 
This study opportunistically accessed seven European population-based electronic 
healthcare databases, to assess their strengths and limitations for routine monitoring of the 
effectiveness of PPPs. The study found a number of limitations in terms of absence of data 
on; prescriptions from secondary care, which are particularly relevant for products with a 
PPP;  data on and induced terminations and spontaneous abortions; compliance with 
contraception and pregnancy testing requirements; information on the indication for 
prescription to assess appropriateness of use, plus difficulties determining the exact timing 
of exposure during or before pregnancy. It was found that no single database or system of 
linked databases contained all the relevant data, but individual countries/databases could 
assess some specific aspects of PPP implementation.  
 
In terms of the strengths of these data sources, the population-based nature provides a 
denominator population which allows the prevalence of prescribing to women of 
childbearing age to be calculated and thus the numbers of women “at risk”, whilst the 
longitudinal nature provides the ability to evaluate trends over time. The prescription data 
are recorded independently by the prescriber or dispensing pharmacist, preventing recall 
bias and it is possible to determine duration of treatment. No data, however, are available 
on whether the product was actually taken or the date when taken. Depending on the 
nature of prescribing of the product under evaluation, some data sources may be more 
useful given their ability to capture data on prescribing in both primary and secondary care; 
however in these databases, data were typically less likely to be available on contraceptive 
prescribing, indication for prescribing and user characteristics, than those capturing data 
from primary care alone. In the databases limited to primary care prescribing, there will be 
some situations where women receive prescriptions from their GP that are normally issued 
in secondary care or where they have them entered into their electronic medical record 
following issue by a specialist; however, there is a question surrounding whether this 
sample of women will be a fully representative subgroup of the population of all female 
users.  
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Our study did not look at the ability to determine the appropriateness of prescribing as a 
major element of risk minimisation. For products such as isotretinoin, future work could 
investigate whether it is possible to determine whether women are appropriately 
prescribed the product as a second-line therapy and whether records of previous 
prescribing of first-line therapies is evident. 
 
For a full evaluation of PPP effectiveness, other elements may also be needed that are not 
captured within electronic healthcare data, for example information on sexual activity, 
healthcare professional or patient knowledge of teratogenic risk and PPP requirements, and 
the different factors women may consider when deciding whether or not to accept the risks 
associated with the product. Qualitative studies, including focus groups, questionnaires and 
interviews, can provide a useful means of obtaining information to help understand the 
difficulties clinicians and patients encounter in implementing PPPs and the way the risk-
benefit ratio is perceived and assessed. In addition, a recent EUROmediCAT study has 
highlighted the potential to purchase isotretinoin, one of the medicines requiring a PPP, 
from the internet bypassing a PPP altogether.[35] None of the databases included in this 
study would capture prescriptions purchased over the internet. 
 
To date, many of the studies reporting on the effectiveness of a PPP in Europe have 
focussed on isotretinoin and have used data collected via surveys/questionnaires,[36-38] a 
medical birth register[39] or one of the European Network of Teratology Information Services 
(ENTIS).[33, 40] These methods of data collection have the benefit of being able to obtain 
information directly from the patient or her prescriber that is not readily available or reliably 
recorded in electronic healthcare databases. However, for studies based on voluntary 
participation, it is not possible to calculate the prevalence of prescribing and there is always 
the possibility that women who opt to take part in the research are not a representative 
sample of the entire population of interest. Two studies, both based in the Netherlands, 
have used data from electronic healthcare databases to evaluate the effectiveness of a PPP 
in terms of contraceptive use.[41, 42] These studies evaluated isotretinoin using data from 
pharmacy prescription databases and both studies found evidence of non-compliance with 
fewer than 60% of women filling prescriptions for contraception. Another study in the 
Netherlands, also using electronic healthcare data, looked at isotretinoin exposure during 
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pregnancy and found that exposed pregnancies do still occur despite the PPP.[43] A French 
study has evaluated compliance with the acitretin PPP using data from the French national 
insurance database (SNIIRAM) and the hospital discharge database. This study focused on 
pregnancy testing and pregnancy occurrence and using data on reimbursed serum βHCG 
and urine laboratory pregnancy tests, found that pregnancy tests were only carried out in 
12% of women starting treatment.[12]  
 
Our study has demonstrated that the electronic healthcare databases evaluated do not 
contain all the data necessary to fully monitor the effectiveness of PPP implementation, and 
thus special data collection measures need to be instituted that would likely benefit from 
including a qualitative data collection component.  The potential for creating special 
prescribing data that can be linked with healthcare databases could also be explored. This is 
relevant also to other teratogenic medications, where measures fall short of a full PPP, such 
as sodium valproate,[44] where specific information on the frequency of prescribing, the 
number of exposed pregnancies and any attempts made to reduce the risk of an unplanned 
exposed pregnancy would be very valuable as part of ongoing post-marketing surveillance. 
The online purchasing of medicines bypassing the PPP is an additional concern which should 
be fully investigated and monitored.[35]  
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Table 1 Summary of the databases contributing to the medicine utilisation component of EUROmediCAT 
Country/Region 
 
Italy - 
Emilia Romagna 
 Italy -   
Tuscany 
Norway 
 
Wales 
 
United Kingdoma Denmark 
 
Netherlands 
 
Database for live & stillbirth 
pregnancy identification 
 
 
Certificate of Delivery 
Assistance (CeDAP) 
 
Certificate of Delivery 
Assistance (CeDAP) 
Hospital Discharges 
Registry 
Medical Birth Registry 
of Norway 
 
 
National 
Community Child 
Health Database 
(NCCHD) 
 
Clinical Practice 
Research Datalink 
 (CPRD)b 
 
Danish National  
Birth Registry 
 
 
IADB.nl Database  
 
 
Database for pregnancy loss 
identification 
 
 
N/A 
 
Discharges for Induced 
Terminations & 
Spontaneous 
Abortions. Hospital 
Discharges Registry 
Medical Birth Registry 
of Norway 
 
 
Patient Episode 
Database for Wales 
(PEDW) 
CARIS for TOPFAsc 
 
Clinical Practice 
Research Datalink 
 
  
Danish National  
Patient Registry 
 
 
 
N/A 
 
Database for medicine  use 
data 
 
Emilia-Romagna 
Prescription Database 
(ERPD) 
Tuscany Prescription 
Database 
(TPD) 
Norwegian 
Prescription Database 
The General 
Practice (GP) 
Dataset 
Clinical Practice 
Research Datalink 
 
Danish  
Prescription 
Registry 
IADB.nl Database 
Source for medicine use data 
 
Pharmacy  
dispensingd 
 
Pharmacy dispensing  
and Healthcare 
Facilities Dispensing 
(except inpatient)8 
 Pharmacy dispensing 
 
GP practice 
prescribing9 
 
 
GP practice 
prescribinge 
 
 
Pharmacy 
dispensing 
 
Pharmacy 
dispensing 
 
Involves database record 
linkage 
Yes 
 
Yes 
 
Yes 
 
Yesf 
 
No 
 
Yes 
 
No 
 
Population base 
 
4,200,000 3,700,000 4,800,000 2,000,000g 5,000,000h  5,000,000i 500,000 
Coverage 
 
Regional Regional National ~70% sample of GP 
practices in Walesj 
~8% sample of the UK 
population 
National Regional  
                                                          
a For the EUROmediCAT study patients registered at a practice in Wales were excluded to avoid duplication with the database in Wales 
b Previously the General Practice Research Database (GPRD) 
c Congenital anomaly and Information Service for Terminations of pregnancy for a fetal anomaly 
d Only products reimbursed by the Italian National Health Service and excluding those dispensed to inpatients 
e Including nurse prescribers working within the GP practice 
f Secure Anonymised Information Linkage (SAIL) databank 
g The Child Health Database and Patient Episode Database capture the whole population of Wales (3 million), whereas the General Practice Dataset currently contains ~2 million records 
h The size of the population captured by the CPRD has grown steadily over time and was approximately 5.0 million in May 2012 
i For the EUROmediCAT study, the data available in the database was restricted to women who had a pregnancy and was not available for the entire population 
jIn 2017 capturing 60% of the population 
 16 
 
Table 2 Summary of available data on prescribing and contraception within each database 
Data available on  Emilia Romagna Tuscany Norway Wales United Kingdom Denmark The Netherlands 
General Practice prescribing Yes Yes Yes Yes Yes Yes Yes 
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11 Excluding those administered during a hospital in-patient stay and those not reimbursed  
12 When prescribing information is passed on to the GP  
13 Excluding those dispensed at a hospital pharmacy 
14 Defined daily dose 
15 Can sometimes be inferred from tablet strength 
16 Inferred from hospital discharge data only 
17 Only broad diagnoses categories were available until the introduction of ICD codes in 2008, after which more specific diagnoses started 
to be recorded 
18 Excluding those from family planning and genitourinary medicine clinics 
19 Excluding those without hormones (e.g. copper devices) 
20 Available in the Norwegian Patient Registry from 2008, although this registry was not included as part of the EUROmediCAT study 
Specialist/outpatient prescribing Yesa Yes11 Yes Occasionally12 Occasionallyb Yes Yes 
Private prescriptions Yes13 No Yes No No Yes Yes  
Inpatient hospital prescribing No No No No No No No 
Date prescription was issued/dispensed Yes Yes Yes Yes Yes Yes Yes 
Quantity issued/dispensed Yes Yes Yes No Majority Yes Yes 
Daily dose/number to take per day DDD14 DDDd DDDd No15 Majority  Sometimes Yes 
Prescription duration/days supplied Can be estimated Can be estimated Can be estimated No Majority No Yes 
Brand/generic Yes Yes Yes Yes Sometimes Yes Yes 
Indication for prescribing No Sometimes16 Sometimes17 Some Majority Sometimesf No 
Oral contraception (OC) No No Yes Yes18 Yeshh Yesi Yes 
     Duration issued/dispensed No No Yes No Yesh No Yes 
Intra-uterine device (IUD) No No Yes19 Yesh Yesh Yesi Yes 
     Date fitted No No No Yesh Yesh Yesi Yes 
     Date removed No No No Yesh Sometimesh No No 
Implanon/Nexplanon/Etonogestrel No No Yes Yesh Yesh Yesi Yes 
     Date inserted No No No Yesh Yesh Yesi Yes 
     Date removed No No No Yesh Sometimesh No No 
Noristerat/Norethisterone enantate No No Yes Yesh Yesh Yesi Yes  
     Date injected No No No Yesh Yesh Yesi Yes 
Depo-Provera No No Yes Yesh Yesh Yesi Yes 
     Date injected No No No Yesh Yesh Yesi Yes 
Record of general contraception advice No No No Occasionallyh Occasionallyh No No 
Hysterectomy No Sometimes Yes20 Yes Majority Yes No 
Oophorectomy No Sometimes Yesj Yes Majority Yes No 
Sterilisation No No Yesj Yes Majority Yes No 
Husband/partner vasectomy No No Yesj Sometimes Sometimes Sometimes No 
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